For example, targeting glutaminase with CB-839 (telaglenastat) and mTOR with MLN128 (sapanisertib) overcomes metabolic adaptation to mTOR inhibition in lung squamous cell carcinoma [271]. This evidence concerns the gene MTOR and squamous cell lung carcinoma.